DK2892330T3 - Genetisk modificeret mus og fremgangsmåder til anvendelse deraf - Google Patents

Genetisk modificeret mus og fremgangsmåder til anvendelse deraf Download PDF

Info

Publication number
DK2892330T3
DK2892330T3 DK13834735.6T DK13834735T DK2892330T3 DK 2892330 T3 DK2892330 T3 DK 2892330T3 DK 13834735 T DK13834735 T DK 13834735T DK 2892330 T3 DK2892330 T3 DK 2892330T3
Authority
DK
Denmark
Prior art keywords
methods
genetically modified
modified mice
mice
genetically
Prior art date
Application number
DK13834735.6T
Other languages
Danish (da)
English (en)
Inventor
Richard A Flavell
Markus Manz
Anthony Rongvaux
Till Strowig
George Yancopoulos
Sean Stevens
Andrew J Murphy
Tim Willinger
Original Assignee
Univ Yale
Regeneron Pharma
Institute For Res In Biomedicine Irb
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale, Regeneron Pharma, Institute For Res In Biomedicine Irb filed Critical Univ Yale
Application granted granted Critical
Publication of DK2892330T3 publication Critical patent/DK2892330T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027New or modified breeds of vertebrates
    • A01K67/0275Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278Knock-in vertebrates, e.g. humanised vertebrates
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027New or modified breeds of vertebrates
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027New or modified breeds of vertebrates
    • A01K67/0271Chimeric vertebrates, e.g. comprising exogenous cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • C07K14/4703Inhibitors; Suppressors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • C07K14/4705Regulators; Modulating activity stimulating, promoting or activating activity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/524Thrombopoietin, i.e. C-MPL ligand
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/53Colony-stimulating factor [CSF]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/53Colony-stimulating factor [CSF]
    • C07K14/535Granulocyte CSF; Granulocyte-macrophage CSF
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/5403IL-3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00Modified animals
    • A01K2207/12Animals modified by administration of exogenous cells
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00Modified animals
    • A01K2207/15Humanized animals
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/07Animals genetically altered by homologous recombination
    • A01K2217/072Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/15Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00Animals characterised by species
    • A01K2227/10Mammal
    • A01K2227/105Murine
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • A01K2267/0331Animal model for proliferative diseases
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • A01K2267/035Animal model for multifactorial diseases
    • A01K2267/0381Animal model for diseases of the hematopoietic system
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • A01K2267/035Animal model for multifactorial diseases
    • A01K2267/0387Animal model for diseases of the immune system

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Environmental Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK13834735.6T 2012-09-07 2013-09-06 Genetisk modificeret mus og fremgangsmåder til anvendelse deraf DK2892330T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261698002P 2012-09-07 2012-09-07
US201361775171P 2013-03-08 2013-03-08
PCT/US2013/058448 WO2014039782A2 (en) 2012-09-07 2013-09-06 Genetically modified non-human animals and methods of use thereof

Publications (1)

Publication Number Publication Date
DK2892330T3 true DK2892330T3 (da) 2023-01-30

Family

ID=50237767

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13834735.6T DK2892330T3 (da) 2012-09-07 2013-09-06 Genetisk modificeret mus og fremgangsmåder til anvendelse deraf

Country Status (18)

Country Link
US (6) US9820476B2 (enExample)
EP (3) EP4193834B1 (enExample)
JP (5) JP6283031B2 (enExample)
KR (7) KR102473555B1 (enExample)
CN (4) CN108782459B (enExample)
AU (3) AU2013312359B8 (enExample)
CA (1) CA2881468C (enExample)
DK (1) DK2892330T3 (enExample)
ES (2) ES2938342T3 (enExample)
FI (1) FI2892330T3 (enExample)
IL (4) IL282472B2 (enExample)
IN (1) IN2015DN02032A (enExample)
MX (2) MX385035B (enExample)
NZ (3) NZ746089A (enExample)
PT (1) PT2892330T (enExample)
RU (2) RU2768282C2 (enExample)
SG (2) SG10201701759VA (enExample)
WO (1) WO2014039782A2 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3417701B1 (en) 2009-10-06 2021-12-15 Regeneron Pharmaceuticals, Inc. Genetically modified mice and engraftment
RU2577978C2 (ru) 2011-02-15 2016-03-20 Ридженерон Фармасьютикалз, Инк. Гуманизированные m-csf мыши
NZ746089A (en) * 2012-09-07 2020-05-29 Institute For Res In Biomedicine Irb Genetically modified non-human animals and methods of use thereof
ES2748662T3 (es) 2012-11-05 2020-03-17 Institute For Res In Biomedicine Irb Roedores inmunodeficientes modificados genéticamente y métodos de uso de los mismos
SMT202500280T1 (it) 2013-09-23 2025-09-12 Regeneron Pharma Animali non umani aventi un gene umanizzato della proteina regolatrice del segnale
TR201904342T4 (tr) 2013-10-15 2019-05-21 Regeneron Pharma Hümani̇ze il-15 hayvanlar
EP3430898A1 (en) 2013-11-19 2019-01-23 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized a proliferation-inducing ligand gene
US9795121B2 (en) 2014-05-05 2017-10-24 Regeneron Pharmaceuticals, Inc. Humanized C3 animals
NO2785538T3 (enExample) 2014-05-07 2018-08-04
KR102821645B1 (ko) 2014-05-19 2025-06-19 리제너론 파마슈티칼스 인코포레이티드 인간 epo를 발현하는 유전자 변형된 비-인간 동물
ES2969389T3 (es) 2014-12-05 2024-05-17 Regeneron Pharma Animales no humanos que tienen un gen del grupo de diferenciación 47 humanizado
EP4399969A3 (en) 2014-12-09 2024-10-30 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized cluster of differentiation 274 gene
AU2015360502A1 (en) 2014-12-10 2017-06-29 Regents Of The University Of Minnesota Genetically modified cells, tissues, and organs for treating disease
SG10202103445QA (en) * 2015-04-13 2021-05-28 Regeneron Pharma Humanized sirpa-il15 knockin mice and methods of use thereof
PT3376857T (pt) 2015-11-20 2021-05-27 Regeneron Pharma Animais não humanos com um gene humanizado 3 de ativação de linfócitos
US10582702B2 (en) 2016-02-04 2020-03-10 Regeneron Pharmaceuticals, Inc. Non-human animals having an engineered ANGPTL8 gene
CA3014645C (en) 2016-02-29 2022-10-25 Regeneron Pharmaceuticals, Inc. Rodents having a humanized tmprss gene
CN106119284A (zh) * 2016-06-27 2016-11-16 北京维通达生物技术有限公司 一种用于构建免疫缺陷动物模型的产品及其应用
JP7458185B2 (ja) * 2016-11-30 2024-03-29 ザ ジャクソン ラボラトリー 改善されたヒト自然免疫細胞の発生を有するヒト化マウスモデル
SG10202112528QA (en) * 2017-05-12 2021-12-30 Jackson Lab Nsg mice lacking mhc class i and class ii
HUE067361T2 (hu) 2018-07-16 2024-10-28 Regeneron Pharma Ditra betegség rágcsáló modelljei és alkalmazásaik
US20210355501A1 (en) * 2018-09-24 2021-11-18 Albert Einstein College Of Medicine Interleukin-8 for maintenance of human acute myeloid leukemia and myelodysplastic syndrome and uses thereof
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN111118019B (zh) * 2018-12-25 2021-03-16 百奥赛图江苏基因生物技术有限公司 人源化细胞因子il3基因改造非人动物的构建方法及应用
CN111073907B (zh) * 2018-12-25 2025-07-29 百奥赛图江苏基因生物技术有限公司 人源化细胞因子csf1基因改造非人动物的构建方法及应用
WO2021011853A2 (en) * 2019-07-17 2021-01-21 Yale University Genetically modified non-human animals and methods of use thereof
US20220408704A1 (en) * 2019-11-01 2022-12-29 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals with human or chimeric thpo
US11339279B2 (en) * 2020-04-01 2022-05-24 Chevron Phillips Chemical Company Lp Dual catalyst system for producing LLDPE and MDPE copolymers with long chain branching for film applications
CN114853871B (zh) * 2021-04-20 2024-04-05 百奥赛图(北京)医药科技股份有限公司 Csf1和/或csf1r基因人源化的非人动物及其构建方法和应用
WO2024020057A1 (en) 2022-07-19 2024-01-25 Regeneron Pharmaceuticals, Inc. Genetically modified animal model and its use to model the human immune system
WO2024259354A1 (en) 2023-06-16 2024-12-19 Regeneron Pharmaceuticals, Inc. Vectors, genetically modified cells, and genetically modified non-human animals comprising the same
US20250255282A1 (en) 2024-02-08 2025-08-14 Regeneron Pharmaceuticals, Inc. Vectors, genetically modified cells, and genetically modified non-human animals comprising the same
WO2025212991A1 (en) 2024-04-05 2025-10-09 Regeneron Pharmaceuticals, Inc. Rodent models of disease

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
US5573930A (en) 1985-02-05 1996-11-12 Cetus Oncology Corporation DNA encoding various forms of colony stimulating factor-1
HU215241B (hu) 1986-10-24 1998-11-30 Cetus Corp. Eljárás telepstimuláló faktor-1 új formáinak előállítására, valamint az eljárásban alkalmazható expressziós kazetta, vektor és rekombináns gazdasejtek előállítására
ES2071620T3 (es) 1987-12-23 1995-07-01 Univ Leland Stanford Junior Mamiferos inmunodeficientes quimericos y su utilizacion.
JP2981486B2 (ja) 1988-06-14 1999-11-22 メディカル・バイオロジー・インスティチュート 哺乳動物の免疫系研究方法
US5849288A (en) 1990-01-15 1998-12-15 Yeda Research And Development Co. Ltd. Method for production of monoclonal antibodies in chimeric mice or rats having xenogeneic antibody-producing cells
US5652373A (en) 1990-01-15 1997-07-29 Yeda Research And Development Co. Ltd. Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems
DE69131331T2 (de) 1990-01-15 2000-03-02 Yeda Research And Development Co., Ltd. Dauerhafte Verpflanzung und Entwicklung menschlicher hämatopoietischer Zellinien bei normalen Säugetieren
DK0481058T3 (da) 1990-05-03 1996-12-02 Systemix Inc Humant, lymfatisk væv i en immunokompromitteret vært
US5633426A (en) 1990-05-25 1997-05-27 Systemix, Inc. In vivo use of human bone marrow for investigation and production
JPH05500617A (ja) 1990-05-25 1993-02-12 システミックス,インコーポレイティド 免疫処理された宿主におけるヒト末梢血液細胞
CA2103705C (en) 1991-02-11 1996-01-30 Ayub K. Ommaya Spinal fluid driven artificial organ
US5222982A (en) 1991-02-11 1993-06-29 Ommaya Ayub K Spinal fluid driven artificial organ
EP0517199A1 (en) 1991-06-04 1992-12-09 Yeda Research And Development Company, Ltd. Durable engraftment of human tissue and cells in normal mammals
WO1993005796A1 (en) 1991-09-19 1993-04-01 The Scripps Research Institute Method for producing human antibodies in a non-human animal, and animals therefor
EP0539970B1 (en) 1991-10-30 1999-05-26 Idemitsu Kosan Company Limited Methods for producing human lymphocytes and human monoclonal antibodies, and human monoclonal antibodies produced thereby
US6353150B1 (en) 1991-11-22 2002-03-05 Hsc Research And Development Limited Partnership Chimeric mammals with human hematopoietic cells
WO1993018144A1 (en) 1992-03-05 1993-09-16 The Trustees Of Columbia University Of The City Of New York Recombination activating gene deficient animal
US5866757A (en) 1992-06-02 1999-02-02 Yeda Research And Development Co. Ltd. Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems
US6018096A (en) 1993-05-03 2000-01-25 Surrogen, Inc. Animal model for engraftment, proliferation and differentiation of human hematopoietic stem cells
CA2103693A1 (en) 1993-08-06 1995-02-07 Steven Gallinger Animal model of the human immune system
WO1996003495A1 (en) 1994-07-27 1996-02-08 Merck & Co., Inc. Bradykinin b2 receptor modified transgenic non-human animals
US6455756B1 (en) 1994-08-12 2002-09-24 Novartis Ag Long term xenogeneic myeloid and lymphoid cell production in chimeric immunocompromised mice
US7273753B2 (en) 1996-08-02 2007-09-25 Center Of Blood Research Purification and uses of dendritic cells and monocytes
US6248721B1 (en) 1997-04-09 2001-06-19 Lung-Ji Chang Method of using mouse model for evaluation of HIV vaccines
EP0973381B1 (en) 1997-04-09 2010-03-03 AMDL, Inc. Animal model for evaluation of vaccines
US20030028911A1 (en) 1999-08-31 2003-02-06 Manley Huang Transgenic mammal capable of facilitating production of donor-specific functional immunity
CA2382383A1 (en) 1999-08-31 2001-03-08 Genencor International, Inc. Transgenic mammal capable of facilitating production of donor-specific functional immunity
JP2004500810A (ja) 1999-12-09 2004-01-15 ヒューマン ジノーム サイエンシーズ, インコーポレイテッド Il−6様ポリヌクレオチド、ポリペプチド、および抗体
WO2002022786A1 (en) 2000-09-14 2002-03-21 Genetrol Biotherapeutics, Inc. Method and cell composition for screening compounds for anti-inflammatory activity
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
WO2003006691A1 (en) * 2001-07-10 2003-01-23 Johnson & Johnson Research Pty Limited Methods for genetic modification of hematopoietic progenitor cells and uses of the modified cells
AU2002363322A1 (en) 2001-10-26 2003-05-19 Large Scale Biology Corporation Endothelial cell derived hemotopoietic growth factor
JP4087338B2 (ja) 2001-11-15 2008-05-21 キリンファーマ株式会社 キメラ非ヒト動物
JPWO2004005496A1 (ja) 2002-07-05 2005-11-04 麒麟麦酒株式会社 臍帯血、骨髄、末梢血等に含まれる新規な未分化幹細胞集団
CN101250553A (zh) 2002-07-13 2008-08-27 上海医学遗传研究所 一种促人血小板生成素表达载体及其构建方法
AU2003278790A1 (en) 2002-09-09 2004-03-29 California Institute Of Technology Methods and compositions for the generation of humanized mice
EP1418185A1 (en) 2002-11-11 2004-05-12 Aventis Pharma Deutschland GmbH Use of EDG2 receptor in an animal model of heart failure
EP1573314B1 (en) 2002-12-16 2008-07-23 Genentech, Inc. Transgenic mice expressing human cd20
EP1802193B1 (en) 2004-10-19 2014-04-30 Regeneron Pharmaceuticals, Inc. Method for generating a mouse homozygous for a genetic modification
US7759541B2 (en) 2004-12-13 2010-07-20 Iti Life Sciences Transgenic animals for assessing drug metabolism and toxicity
GB2434578A (en) 2006-01-26 2007-08-01 Univ Basel Transgenic animals
SI2019683T2 (sl) 2006-04-25 2022-10-28 The Regents Of The University Of California Dajanje rastnih faktorjev za zdravljenje motenj CŽS
EP1878342A1 (en) 2006-07-13 2008-01-16 Institut Pasteur Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses
WO2008060360A2 (en) 2006-09-28 2008-05-22 Surmodics, Inc. Implantable medical device with apertures for delivery of bioactive agents
WO2008069659A1 (en) 2006-12-05 2008-06-12 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Improved xenogenic immune system in a non-human mammal
CA2687688C (en) 2007-05-23 2017-03-28 Sangamo Biosciences, Inc. Methods and compositions for increased transgene expression in t cells
GB0718029D0 (en) 2007-09-14 2007-10-24 Iti Scotland Ltd Two step cluster deletion and humanisation
US20110118446A1 (en) 2007-09-28 2011-05-19 The General Hospital Corporation Methods and compositions for antibody production
CN101970478A (zh) * 2007-10-11 2011-02-09 大学健康网络 调节SIRPα-CD47相互作用以增加造血干细胞植入以及用于此的化合物
EP2257250A2 (en) 2008-01-29 2010-12-08 Gilbert H. Kliman Drug delivery devices, kits and methods therefor
JP2012531894A (ja) * 2009-06-29 2012-12-13 レスコフ,イリヤ,ビー. ヒト血液癌の非ヒト哺乳動物モデル
CN102725400A (zh) * 2009-06-29 2012-10-10 麻省理工学院 制造人源化的非人类哺乳动物的方法
RU2425880C2 (ru) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
EP3417701B1 (en) * 2009-10-06 2021-12-15 Regeneron Pharmaceuticals, Inc. Genetically modified mice and engraftment
EP2618656B1 (en) * 2010-09-20 2018-06-20 Yale University, Inc. HUMAN SIRPalpha TRANSGENIC ANIMALS AND THEIR METHODS OF USE
WO2012051572A1 (en) 2010-10-15 2012-04-19 Massachusetts Institute Of Technology A humanized non-human mammal model of malaria and uses thereof
RU2577978C2 (ru) 2011-02-15 2016-03-20 Ридженерон Фармасьютикалз, Инк. Гуманизированные m-csf мыши
RU2751240C2 (ru) 2011-10-28 2021-07-12 Регенерон Фармасьютикалс, Инк. Гуманизированные il-6 и рецептор il-6
NZ746089A (en) 2012-09-07 2020-05-29 Institute For Res In Biomedicine Irb Genetically modified non-human animals and methods of use thereof
ES2748662T3 (es) 2012-11-05 2020-03-17 Institute For Res In Biomedicine Irb Roedores inmunodeficientes modificados genéticamente y métodos de uso de los mismos
SMT202500280T1 (it) 2013-09-23 2025-09-12 Regeneron Pharma Animali non umani aventi un gene umanizzato della proteina regolatrice del segnale
TR201904342T4 (tr) 2013-10-15 2019-05-21 Regeneron Pharma Hümani̇ze il-15 hayvanlar
KR102821645B1 (ko) 2014-05-19 2025-06-19 리제너론 파마슈티칼스 인코포레이티드 인간 epo를 발현하는 유전자 변형된 비-인간 동물
SG10202103445QA (en) 2015-04-13 2021-05-28 Regeneron Pharma Humanized sirpa-il15 knockin mice and methods of use thereof

Also Published As

Publication number Publication date
KR102645622B1 (ko) 2024-03-11
KR102241962B1 (ko) 2021-04-20
AU2019216625B2 (en) 2021-07-08
AU2021240324A1 (en) 2021-10-28
EP4606818A3 (en) 2025-10-22
RU2015112607A (ru) 2016-10-27
RU2642319C2 (ru) 2018-01-24
US11026408B2 (en) 2021-06-08
IL265570B (en) 2021-05-31
JP2015529083A (ja) 2015-10-05
CN120718856A (zh) 2025-09-30
CN108782459B (zh) 2021-11-05
EP4193834B1 (en) 2025-05-14
CN113897398A (zh) 2022-01-07
WO2014039782A2 (en) 2014-03-13
IL307969B1 (en) 2025-10-01
MX2019005251A (es) 2019-08-05
KR20150052274A (ko) 2015-05-13
MX364714B (es) 2019-05-06
AU2019216625A1 (en) 2019-09-05
EP2892330B1 (en) 2022-11-23
CN108782459A (zh) 2018-11-13
KR102594390B1 (ko) 2023-10-27
FI2892330T3 (fi) 2023-03-25
JP2019110922A (ja) 2019-07-11
CN104955326A (zh) 2015-09-30
CN104955326B (zh) 2018-07-20
AU2013312359B8 (en) 2019-08-15
AU2021240324B2 (en) 2024-02-22
EP4193834C0 (en) 2025-05-14
KR20210044315A (ko) 2021-04-22
IN2015DN02032A (enExample) 2015-08-14
IL236877A0 (en) 2015-03-31
IL265570A (en) 2019-05-30
ES3034290T3 (en) 2025-08-14
AU2013312359B2 (en) 2019-05-23
NZ746089A (en) 2020-05-29
SG11201500504RA (en) 2015-02-27
JP2020168024A (ja) 2020-10-15
JP6517958B2 (ja) 2019-05-22
US20180020647A1 (en) 2018-01-25
CN113897398B (zh) 2025-07-08
RU2768282C2 (ru) 2022-03-23
RU2017145913A (ru) 2019-02-19
EP4606818A2 (en) 2025-08-27
US20190082663A1 (en) 2019-03-21
PT2892330T (pt) 2023-02-17
EP4193834A1 (en) 2023-06-14
KR20220164808A (ko) 2022-12-13
JP6283031B2 (ja) 2018-02-21
JP2022105531A (ja) 2022-07-14
US20210368752A1 (en) 2021-12-02
EP2892330A2 (en) 2015-07-15
IL307969A (en) 2023-12-01
US12127537B2 (en) 2024-10-29
US20150208622A1 (en) 2015-07-30
HK1211176A1 (en) 2016-05-20
KR102340059B1 (ko) 2021-12-17
AU2013312359A1 (en) 2015-02-19
JP6732998B2 (ja) 2020-07-29
KR20240045263A (ko) 2024-04-05
US20200093105A1 (en) 2020-03-26
MX2015002983A (es) 2015-06-17
NZ704957A (en) 2018-05-25
WO2014039782A3 (en) 2015-07-23
KR20230153500A (ko) 2023-11-06
EP2892330A4 (en) 2016-07-27
JP7066785B2 (ja) 2022-05-13
US20250072405A1 (en) 2025-03-06
NZ741951A (en) 2020-04-24
KR102473555B1 (ko) 2022-12-05
IL282472B1 (en) 2023-12-01
SG10201701759VA (en) 2017-04-27
KR20210099664A (ko) 2021-08-12
RU2017145913A3 (enExample) 2021-08-16
KR102287541B1 (ko) 2021-08-10
JP7605789B2 (ja) 2024-12-24
CA2881468A1 (en) 2014-03-13
MX385035B (es) 2025-03-14
ES2938342T3 (es) 2023-04-10
US10433527B2 (en) 2019-10-08
JP2018088925A (ja) 2018-06-14
US9820476B2 (en) 2017-11-21
KR20210156846A (ko) 2021-12-27
IL282472A (en) 2021-06-30
CA2881468C (en) 2023-03-21
AU2013312359A8 (en) 2019-08-15
IL282472B2 (en) 2024-04-01

Similar Documents

Publication Publication Date Title
DK2892330T3 (da) Genetisk modificeret mus og fremgangsmåder til anvendelse deraf
DK3939423T3 (da) Genetisk modificerede ikke-humane dyr og fremgangsmåder til anvendelse deraf
DK2900657T3 (da) Cykliske etherpyrazol-4-yl-heterocyclyl-carboxamidforbindelser og fremgangsmåder til anvendelse
DK2844292T3 (da) ST2L-antagonister og fremgangsmåder til anvendelse
DK2929031T5 (da) Pcsk9-irna-sammensætninger og fremgangsmåder til anvendelse deraf
PL2525979T3 (pl) Układy i sposoby obróbki jaj i innych przedmiotów
DK3978522T3 (da) Humane antistoffer over for Fel D1 og fremgangsmåder til anvendelse deraf
DK2852680T3 (da) Fremgangsmåder og processer til ikke-invasiv evaluering af genetiske variationer
DK2914627T3 (da) Anti-cd40-antistoffer og fremgangsmåder til anvendelse
DK2914633T3 (da) Antistof/lægemiddel-konjugater og anvendelsesfremgangsmåder
DK2850202T3 (da) Fremgangsmåder og grupper
DK2675827T3 (da) Hidtil ukendte modulatorer og fremgangsmåder til anvendelse
PL2812443T3 (pl) Przeciwciała CD47 i sposoby ich zastosowania
DK3262932T3 (da) Genmodificerede mus med major histokompatibilitetskompleks
DK2579877T3 (da) Morpholinopyrimidiner og deres anvendelse til terapi
DK2683731T3 (da) C4-monomethyl-triterpenoidderivater og fremgangsmåder til anvendelse deraf
DK2903600T3 (da) Virusholdig formulering og anvendelse deraf
HRP20182037T1 (hr) Inhibitori prmt5 i njihova uporaba
EP2856081A4 (en) MULTI-ACTIVITY PLATFORM AND INTERFACE
DK3192812T3 (da) Anti-CD3-antistoffer og fremgangsmåder til anvendelse
DK2920313T3 (da) Rekombinante adenovira og anvendelse deraf
DK2914291T3 (da) Anti-komplement-c1s-antistoffer og anvendelser deraf
DK2872153T3 (da) Accellulære pro-tolerogene sammensætninger og fremgangsmåde til fremstilling heraf
DK2882496T3 (da) Behandling og diagnosticering af melanom
DK3489254T3 (da) Målrettede/immunmodulatoriske fusionsproteiner og fremgangsmåder til fremstilling deraf